期刊文献+

在猪组织笼内恩诺沙星对大肠杆菌的药效研究

Pharmacokinetic effects of enrofloxacin against Escherichia coli in tis sue cage of pigs
下载PDF
导出
摘要 为了合理应用恩诺沙星治疗猪大肠杆菌感染,采用猪体内安装组织笼的方法,研究感染组织笼用药后,组织笼内大肠杆菌数量的变化。结果表明,恩诺沙星在不同大小的组织笼内的药动学特征不同,在小组织笼内的半衰期明显大于在大组织笼内的半衰期,在相同大小的组织笼内随着药物浓度的增加半衰期表现为增长。感染笼注射恩诺沙星前后细菌的生长繁殖情况亦有不同,在大组织笼和小组织笼内,无药对照笼内的细菌在试验的过程中细菌的数量均基本上保持恒定,大组织笼内注入2MIC的恩诺沙星后,细菌在被抑制9 h后,出现再生长现象,而在小组织笼内细菌在被抑制12 h后,出现再生长现象。注入5MIC或8MIC的恩诺沙星后,大小组织笼内的5MIC和8MIC的细菌杀菌曲线几乎重合,并都在24 h后,在组织笼内检测不到细菌。细菌在接触药物的早期阶段下降最为迅速。通过分析认为,如果药物在体内消除慢,可以适当减少抗菌药物的用量。 For researching the usage of enrofloxacin against Escherichia coil, the method of tissue cage was used to survey the amount of Escherichia coil in tissue cage after administration. The results showed that on the pharmacokinetic characters of enrofloxacin was between different big and small tissue cages. The half-life of enrofloxacin in small tissue cage was more than that in big one. The half-life in the same tissue cage would increase as the concentration increased of enrofloxacin. The growing character of Escherichia coli in tissue cage was different before and after administration. The amount of Escherichia coli in control tissue cage was almost stable. Escherichia coli was inhibited for 9 h and regrowed in big tissue cage, and was inhibited for 12 h in small one after 2MIC enrofloxacin injected. The killing curve of 5MIC and 8MIC of enrofloxacin against Escherichia coli was almost coincidence, Escherichia coli would be not detected after 24 h of administration in big tissue cage and in small one. The bacteria quickly decreased in initiation stage of contacting enrofloxacin in tissue cages. The dosage of enrofloxacin should be decreased if the half-life was longer by analyzing.
出处 《东北农业大学学报》 CAS CSCD 北大核心 2012年第12期86-91,共6页 Journal of Northeast Agricultural University
基金 国家自然科学基金(30600451 31172363) 海南省自然科学基金项目(311034)
关键词 恩诺沙星 大肠杆菌 体内 药动-药效同步 enrofloxacin Escherichia coil in vivo pk-pd
  • 相关文献

参考文献18

  • 1Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of anti-microbial pharmacokinetic parameters with therapeutic efficacy inan animal model[J]. J Infect Dis, 1988, 158(4): 831-847.
  • 2Legget J E, Ebert S, Fantin B, et al. Comparative dose-effectrelations ant several dosing intervals for betalactam, aninogly-coside and quinolone antibiotics against gram-negative bacilli inmurine thigh-infection and pneumonitis models[J]. Scand J ofInfect Dis. 1990, 74(Suppl.): 179-184.
  • 3Ramadan A, Afifina, Osman K M,et al. Pharmacokinetics andpharmacodynamics of gentamicin in experimentally pseudo-monas aeruginosa-infected Chickens[C]//. Proceedings of 6thinternational Congress. Boston: Blackwell Scientific Publications,1994:61-62.
  • 4Wright D H, Brown G H, Peterson M L, et al. Application of fluo-roquinlone pharmacodynamics[J]. J Antimicrob Chemoth, 2000,46 (5):669-683.
  • 5Bengtsson B, Greko C. Simulation of concentration-time profilesof benzyl-penicillin, enrofloxacin and dihydrostreptomycin intissue cages in calvesfj]. J vet Pharmacol. Therap, 2002, 25(5):389-392.
  • 6Greko C, Finn M,Ohagen P, et al. A tissue cage model in calvesfor studies on pharmacokinetic/pharmacodynamic interactions ofantimicrobials[J]. Int J Antimicrob Ag, 2003,22(4): 429-438.
  • 7Kaye D, Parsons J N, Carrizosa, et al. Treatment of experimentalStaphylococcus aureus abscesses: Comparison of cefazolin, cepha-lothin, cefoxitin, and cefamandole[J]. Antimicrob Agents Ch,1979,15(2):200-203.
  • 8Roos K, Brorson J E, Holm S E. Studies in vivo on the killing rateand refractory period of penicillin V in an experimental strepto-coccal infection[J]. J Antimicrob Chemoth, 1985, 15(5): 587-595.
  • 9Readle R E, Short C R,Corstvet R E, et al. Characteriztion of asoft tissue infection model in the horse and its response to intrave-nous cephapirin administration[J]. J Vet Pharmacol Ther, 1989,12(1):73-86.
  • 10Clark C R, Short C R, Corstvet R E, et al. Effect of Pasteurellahaemolytica infection on the distribution of sulfadiazine andtrimethoprim into tissue chambers implanted subcutaneously incattle[J]. Am J Vet Res, 1989, 50(9): 1551-1565.

二级参考文献23

  • 1曾振灵,冯淇辉.恩诺沙星在猪体内的生物利用度及药物动力学研究[J].中国兽医学报,1996,16(6):606-612. 被引量:45
  • 2杨雨辉,丁焕中,杨东,曾振灵.抗菌药物药动、药效同步信息在兽医临床上应用的研究进展[J].中国兽药杂志,2006,40(11):20-24. 被引量:6
  • 3杨雨辉,丁焕中,杨东,曾振灵,刘文字.体外药动学模型中恩诺沙星对猪大肠杆菌的药效研究[J].中国兽医科学,2007,37(7):636-640. 被引量:8
  • 4夏文江 成章瑞.MCPKP-药物动力学室分析的一种微机程序[J].中国药理学报,1988,9:188-188.
  • 5EPSTEIN B J, GUMS J G, DRLICA K. The chan-ging face of antibiotic prescribing: The mutant selec- tion window[J]. Ann Pharmacother, 2004,38 : 1675- 1682.
  • 6SHOJAEE A F, LEES P. Pharmacokenetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudates and transudate [JJ. J Vet Pharmacol Therap, 2002,25:161-174.
  • 7ALIABADI F S, ALI B H, LANDONI M F, et al. Pharmacokenetics and PK-PD modeling of danofloxa- cin in camel serum and tissue cage fluids[J]. Vet J , 2003, 165 : 104-118.
  • 8SHOJAEE A F, LANDONI M F, LEES P. Pharma- cokenetics (PK), Pharmacodynamics (PD), and PK- PD integration of danofloxaein in sheep biological flu- ids[J]. Antimicrobial Agents and Chemotherapy, 2003, 47(2) :626-635.
  • 9YOSHITAKA Y,TAKAYOSHI O,HIROSHI N,et al.Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics[J].J Pharm Sci,1998,87(10):1177-1182.
  • 10SARASOLA P,LEES P,ALIABADI F S,et al.Pharmacokinetic and pharmacodynamic profile of danafloxacin administrated by two dosing regimens in calves infected with Mannheimia (Pasteurella)haemolytica[J].Antimicrob Agents Chemother,2002.46(7):3013-3019.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部